SMA Peg denied as not FDA-approved for this use by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied This Claim — and Why It's Appealable

A "not FDA-approved" denial for a pegylated SMA therapy is one of the most directly disputable denial categories: if the FDA has approved the drug for the indication being treated, the denial is factually incorrect and should be reversed upon presentation of the approval documentation. If the drug is being prescribed off-label (outside its approved indication), the analysis is more nuanced — but ERISA and many state laws still require coverage when off-label use is supported by recognized clinical evidence compendia or guidelines.

## Your Federal Appeal Rights

ACA §2719 entitles you to a full internal appeal and independent external review by an IRO. ERISA §503 requires a full and fair review. The external review window is generally four months from the denial date. For an on-label prescription, an IRO will almost invariably reverse a "not FDA-approved" denial once the approval documentation is presented. Expedited review is available where delay would seriously jeopardize health.

## Concrete Appeal Steps

1. Confirm the approval status of the specific drug and indication using the FDA's Drugs@FDA database — retrieve the current prescribing information and the original approval letter. 2. Determine whether the prescription is on-label or off-label for this patient's SMA type and clinical profile. 3. For on-label prescriptions: File a Level 1 internal appeal attaching the FDA approval letter and prescribing information, with a cover letter identifying the specific approval Anthem's denial overlooks. 4. For off-label prescriptions: Build an appeal citing recognition in applicable evidence compendia (e.g., NCCN Drugs & Biologics Compendium, or the relevant specialty organization's guidance) and state law provisions on off-label coverage. 5. Escalate to external review if Level 1 is upheld.

## Documentation to Gather

• FDA approval documents: Prescribing information (full label) and approval letter from Drugs@FDA.
• Indication alignment: Excerpt from the label's indication section alongside the physician's diagnosis documentation, showing the patient falls within the approved population.
• Diagnosis confirmation: Genetic test confirming SMA type; clinical notes establishing the treating indication.
• Prescriber medical-necessity letter: Explains how the prescription aligns with the FDA-approved labeling and the applicable guideline organization's recommendations.
• Off-label support (if applicable): Copies of compendia listings and relevant guideline sections, without citing specific statistics, to demonstrate recognized use.

## Criteria-Mapping Structure

For a not-FDA-approved denial, the mapping is straightforward: left column lists each basis for Anthem's denial; right column provides the FDA document or guideline reference that directly refutes it. Attach all source documents as exhibits so the reviewer does not need to locate them independently.